market-trends is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Chiesi Global Rare Diseases, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Protalix BioTherapeutics
market-trends is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Chiesi Global Rare Diseases, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window. At 5, the average consequence score sits below the same-window beat average of 5.8. We currently track 1 Healthcare story that mention Protalix BioTherapeutics, all published on March 18, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 24 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Protalix BioTherapeutics. Shared-story counts are live from our verified record — not editorial picks.
Protalix BioTherapeutics reported misses on both top-line and bottom-line estimates for the fiscal year 2026, reflecting ongoing challenges in the rare disease therapeutic market. Despite the shortfall, the company provided a forward-looking outlook for FY26, signaling a focus on long-term clinical development and commercialization of its plant-based protein expression platform.